Advertisement
- Furthermore, Combining Imatinib (Gleevec(R)), a Targeted Cancer DrugApproved Treatment of Chronic Myelogenous Leukemia (CML) and GastrointestinalStromal Tumors Manufactured by Novartis, With miR-451 had a SynergisticEffect in Inhibiting GBM Growth
Advertisement
- miR-451 was First Disclosed in a Patent Application by Rosetta Genomicsand is Currently Under Active Examination
Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today that a collaborativestudy published by scientists from the Weizmann Institute of Science andscientists at Sheba Medical Center, with the aid of Rosetta Genomics, hasdemonstrated that a microRNA first disclosed by the company increased theefficacy of Imatinib (Gleevec(R)) in Glioblastoma (GBM), the most common andmost aggressive type of primary brain tumor.
"We are excited to be part of this important study led by the renownedscientists from the Weizmann Institute of Science and from the Sheba MedicalCenter," noted Dr. Dalia Cohen, Chief Scientific Officer at Rosetta Genomics."MicroRNAs are quickly emerging as major regulators of biological processesand have wide diagnostic and therapeutic potential. Rosetta Genomics'extensive intellectual property portfolio which includes the first everissued patent relating to microRNAs, as well as patent applications for alarge portion of today's known microRNAs, positions us to lead the microRNAspace and advance patient care worldwide. Our first microRNA-based products,diagnosing various cancers, are expected to be launched later this year."
In the study, "MIR-451 and Imatinib Mesylate Inhibit the Growth ofGlioblastoma Stem Cells", published online in Biochemical and BiophysicalResearch Communications, scientists demonstrated that overexpressing miR-451in-vitro caused inhibition of GBM cell growth. In addition, when combiningImatinib (Gleevec(R)), a targeted therapy manufactured by Novartis andapproved treatment of CML and gastrointestinal stromal tumors, with miR-451,a synergistic effect has been shown in inhibiting GBM cell proliferation.
Imatinib (Gleevec(R)) is the first approved drug to directly inhibit aprotein known to cause a cancer. Several studies have been, and are currentlybeing conducted, to examine the drug's effectiveness in treating GBM.
About microRNAs
MicroRNAs (miRNAs) are recently discovered, naturally occurring, smallRNAs that act as master regulators and have the potential to form the basisfor a new class of diagnostics and therapeutics. Since many diseases arecaused by the abnormal activity of proteins, the ability to selectivelyregulate protein activity through microRNAs could provide the means to treata wide range of human diseases. In addition, microRNAs have been shown tohave different expression in various pathological conditions. As a result,these differences may provide for a novel diagnostic strategy for manydiseases.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA.Founded in 2000, the company's integrative research platform combiningbioinformatics and state-of-the-art laboratory processes has led to thediscovery of hundreds of biologically validated novel human microRNAs.Building on its strong IP position and proprietary platform technologies,Rosetta Genomics is working on the application of these technologies in thedevelopment of a full range of microRNA-based diagnostic and therapeutictools, focusing primarily on cancer and various women's health indications.The first test based on the company's technology, differentiating squamousfrom non squamous non small cell lung canc
